DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0113314 A1 Fong Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0113314 A1 Fong Et Al US 20050113314A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0113314 A1 Fong et al. (43) Pub. Date: May 26, 2005 (54) CICLETANINE IN COMBINATION WITH Publication Classification ORAL ANTIDIABETIC AND/OR BLOOD LIPID-LOWERING AGENTS ASA COMBINATION THERAPY FOR DIABETES (51) Int. Cl." ..................... A61K 31/70; A61K 31/4741; AND METABOLIC SYNDROME A61K 31/426; A61K 31/155; A61K 31/175 (76) Inventors: Benson M. Fong, San Francisco, CA (52) U.S. Cl. ............................ 514/25; 514/302; 514/369; (US); Glenn V. Cornett, Palo Alto, CA 514/592; 514/635 (US) Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP 2040 MAIN STREET (57) ABSTRACT FOURTEENTH FLOOR IRVINE, CA 92614 (US) Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for (21) Appl. No.: 10/929,108 treating and/or preventing complications in patients with (22) Filed: Aug. 27, 2004 diabetes and/or metabolic Syndrome. More particularly, aspects of the present invention are related to using a Related U.S. Application Data combination of cicletanine and an oral antidiabetic agent for treating and/or preventing complications (including microal (60) Provisional application No. 60/498,916, filed on Aug. buminuria, nephropathies, retinopathies and other compli 29, 2003. cations) in patients with diabetes or metabolic Syndrome. US 2005/0113314 A1 May 26, 2005 CICLETANNE IN COMBINATION WITH ORAL women >0.85) and/or Body Mass Index >30 kg/M); 6) ANTIDIABETIC AND/OR BLOOD micro albuminuria (urine albumin excretion: 220 ugmin' LIPID-LOWERING AGENTS ASA COMBINATION or albumin/creatinine ratio22.0 mg/mmol. THERAPY FOR DIABETES AND METABOLIC 0007. In the chronological sequence of impaired glucose SYNDROME tolerance, followed by early and late phases of type 2 diabetes, it is essential to Start early with nonpharmacologic RELATED APPLICATIONS therapy, including physical activity, diet, and weight reduc 0001) This application claims the benefit of UA Provi tion. In addition, to reduce the incidence of macrovascular sional Patent Application No. 60/498,916 filed Aug. 29, complications of diabetes, pharmacotherapy for distur 2003, which is expressly incorporated herein by reference in bances in lipid metabolism and for hypertension is war its entirety. ranted (Goldberg, R. et al. 1998 Circulation 98:2513-2519; Pyorala, K. et al. 1997 Diabetes Care 20:614-620). There FIELD OF THE INVENTION fore, it has become increasingly evident that the treatment should aim at Simultaneously normalizing blood glucose, 0002 Preferred embodiments of the present invention are blood preSSure, lipids and body weight to reduce the mor related to using a combination of cicletanine and an oral bidity and mortality. Unfortunately, until today no single antidiabetic agent and/or a blood-lipid-lowering agent for drug that Simultaneously attackS hyperglycemia, hyperten treating and/or preventing complications (including microal Sion and dyslipidemia is available for patients with meta buminuria, nephropathies, retinopathies and other compli bolic Syndrome. cations) in patients with diabetes or metabolic Syndrome, for controlling blood glucose, and a combination of cicletanine 0008. In general, there are three pharmacotherapeutic and a lipid-lowering agent for controlling blood lipids and approaches typically relevant to the management of meta treating metabolic Syndrome. bolic Syndrome (insulin resistance Syndrome, Syndrome X): 0009 1) Hypoglycemic agents: A) Oral antidiabet BACKGROUND OF THE INVENTION ics (OADS); B) Insulin; 0.003 Diabetes is a chronic metabolic disorder which 0010) 2) Antihypertensive agents; afflicts 14 million people in the United States, over two 0011 3) Lipid-lowering agents. million of whom have its most severe form, childhood diabetes (also called juvenile, Type I or insulin-dependent 0012 Drug toxicity is an important consideration in the diabetes). Type II Diabetes (DM II) makes up more than treatment of humans and animals. Toxic side effects result 85-90% of all diabetics, and is likely to be the next epidemic. ing from the administration of drugs include a variety of 0004 Patients with diabetes of all types have consider conditions that range from low-grade fever to death. Drug able morbidity and mortality from microvascular (retinopa therapy is justified only when the benefits of the treatment thy, neuropathy, nephropathy) and macrovascular (heart protocol outweigh the potential risks associated with the attacks, Stroke, peripheral vascular disease) pathology, all of treatment. The factors balanced by the practitioner include which carry an enormous cost. For example: a) Proliferative the qualitative and quantitative impact of the drug to be used retinopathy (the leading cause of blindness for people under as well as the resulting outcome if the drug is not provided 65 years of age in the United States) and/or macular edema to the individual. Other factors considered include the physi occur in about 50% of patients with type 2 diabetes, as do cal condition of the patient, the disease Stage and its history peripheral and/or autonomic neuropathy. b) The incidence of of progression, and any known adverse effects associated diabetic renal disease is 10% to 50% depending on ethnicity. with a drug. c) Diabetics have heart attacks, Strokes and peripheral vas 0013. It is known that, for example, Sulfonylureas can cular disease at about triple the rate of non-diabetics. The cause Severe and lifethreatening hypoglycemia, due to their cost of treating diabetes and its complications exceeds S100 continuous action as long as they are present in the blood billion annually. (Holman, R. R. & Turner, R. C., 1991 In: Textbook of Diabetes, Pickup, J. C., Williams, G., Eds; Blackwell Sci 0005 Non-insulin dependent diabetes mellitus develops entific Publ. London, pp. 462-476). Such an action may especially in Subjects with insulin resistance and a cluster of affect the myocytes in the heart increasing the risk of cardiac cardiovascular risk factorS Such as obesity, hypertension and arrhythmias. On the other hand, metformin is known to dyslipidemia, a Syndrome which first recently has been cause Stomach-malfunction and toxicity which can cause recognized and is named “The metabolic Syndrome' death by excessive dose of administration to a patient for a (Alberti K. G., & Zimmet P. Z. 1998 Diabet Med 7:539-53). prolonged time (Innerfield, R. J. 1996 New Engl J Med 0006. In accordance with the WHO definition, a patient 334:1611-1613). Glitazones (e.g., Actos(R), Avandia(R), Rezu has metabolic Syndrome if insulin resistance and/or glucose lin(E); also known as the thiazolidinediones) tend to increase intolerance is present together with two or more of the lipids. TroglitaZone is known to have side effects, Such as following conditions: 1) reduced glucose tolerance or dia anemia, nausea, and hepatic toxicity (Eung-Jin Lee et al. betes; 2) insulin Sensitivity (under hyperinsulinemic, eugly 1998 Diabetes Science, Korea Medicine, 345-359; Ishii, S. cemic conditions corresponding to a glucose uptake below et al. 1996 Diabetes 45: (Suppl. 2), 141A (abstracts) Wat the lower quartile for the background population); 3) king, P. B. et al. 1998 N Engl J Med 338:916-917). Other increased blood pressure (2140/90 mmHg); 4) increased reported adverse events include dyspnea, headache, thirst, plasma triglyceride (21.7 mmol/l) and/or low HDL choles gastrointestinal distreSS, insomnia, dizziness, incoordina terol (<0.9 mmol/l for men; <1.0 mmol/l for women); 5) tion, confusion, fatigue, pruritus, rash, alterations in blood central adipositas (waist/hip ratio for men: >0.90 and for cell counts, changes in Serum lipids, acute renal insuffi US 2005/0113314 A1 May 26, 2005 ciency, and dryneSS of the mouth. Additional Symptoms that mitigate a Side effect of Said Second agent. In another have been reported, for which the relationship to troglita variation, the therapeutically effective amount of cicletanine Zone is unknown, include palpitations, Sensations of hot and is Sufficient to enhance tissue Sensitivity to insulin. Alterna cold, Swelling of body parts, skin eruption, Stroke, and tively, the therapeutically effective amount of cicletanine hyperglycemia. and the blood glucose lowering amount of the Second agent are preferably Sufficient to produce a Synergistic glucose 0.014 Consequently there is a long felt need for a new and lowering effect. combined medicament for the treatment of diabetes, and pre-diabetic, metabolic Syndrome, that has fewer, or no, 0023. In another embodiment, a method is disclosed for adverse effects (i.e., less toxicity) and favorable profile in treating and/or preventing a condition associated with terms of blood glucose and lipids. elevated cholesterol in a mammal. The method comprises administering an oral formulation comprising a therapeuti SUMMARY OF THE INVENTION cally effective amount of cicletanine and a lipid lowering 0.015. In accordance with one preferred embodiment of amount of a Second agent. the present invention, an oral formulation is disclosed, 0024 Preferably, the second agent is selected from the comprising a therapeutically effective amount of cicletanine group consisting of cholestyramine, colestipol, lovastatin, in combination with a Second agent that lowers blood pravastatin, Simvastatin, gemfibrozil, clofibrate, nicotinic glucose. acid and probucol. Alternatively, the Second agent is an 0016. In one preferred variation, the cicletanine com HMG-CoA reductase inhibitor. prises
Load more

Recommended publications
  • In Silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction
    In silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction Pathima Nusrath Hameed ORCID: 0000-0002-8118-9823 Submitted in total fulfilment of the requirements for the degree of Doctor of Philosophy Department of Mechanical Engineering THE UNIVERSITY OF MELBOURNE May 2018 Copyright © 2018 Pathima Nusrath Hameed All rights reserved. No part of the publication may be reproduced in any form by print, photoprint, microfilm or any other means without written permission from the author. Abstract Drug repositioning and drug-drug interaction (DDI) prediction are two fundamental ap- plications having a large impact on drug development and clinical care. Drug reposi- tioning aims to identify new uses for existing drugs. Moreover, understanding harmful DDIs is essential to enhance the effects of clinical care. Exploring both therapeutic uses and adverse effects of drugs or a pair of drugs have significant benefits in pharmacology. The use of computational methods to support drug repositioning and DDI prediction en- able improvements in the speed of drug development compared to in vivo and in vitro methods. This thesis investigates the consequences of employing a representative training sam- ple in achieving better performance for DDI classification. The Positive-Unlabeled Learn- ing method introduced in this thesis aims to employ representative positives as well as reliable negatives to train the binary classifier for inferring potential DDIs. Moreover, it explores the importance of a finer-grained similarity metric to represent the pairwise drug similarities. Drug repositioning can be approached by new indication detection. In this study, Anatomical Therapeutic Chemical (ATC) classification is used as the primary source to determine the indications/therapeutic uses of drugs for drug repositioning.
    [Show full text]
  • Interactions Medicamenteuses Index Des Classes Pharmaco
    INTERACTIONS MEDICAMENTEUSES INDEX DES CLASSES PHARMACO-THERAPEUTIQUES Mise à jour avril 2006 acides biliaires (acide chenodesoxycholique, acide ursodesoxycholique) acidifiants urinaires adrénaline (voie bucco-dentaire ou sous-cutanée) (adrenaline alcalinisants urinaires (acetazolamide, sodium (bicarbonate de), trometamol) alcaloïdes de l'ergot de seigle dopaminergiques (bromocriptine, cabergoline, lisuride, pergolide) alcaloïdes de l'ergot de seigle vasoconstricteurs (dihydroergotamine, ergotamine, methylergometrine) alginates (acide alginique, sodium et de trolamine (alginate de)) alphabloquants à visée urologique (alfuzosine, doxazosine, prazosine, tamsulosine, terazosine) amidons et gélatines (gelatine, hydroxyethylamidon, polygeline) aminosides (amikacine, dibekacine, gentamicine, isepamicine, kanamycine, netilmicine, streptomycine, tobramycine) amprénavir (et, par extrapolation, fosamprénavir) (amprenavir, fosamprenavir) analgésiques morphiniques agonistes (alfentanil, codeine, dextromoramide, dextropropoxyphene, dihydrocodeine, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil, tramadol) analgésiques morphiniques de palier II (codeine, dextropropoxyphene, dihydrocodeine, tramadol) analgésiques morphiniques de palier III (alfentanil, dextromoramide, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil) analogues de la somatostatine (lanreotide, octreotide) androgènes (danazol, norethandrolone, testosterone) anesthésiques volatils halogénés
    [Show full text]
  • DIURETICS Diuretics Are Drugs That Promote the Output of Urine Excreted by the Kidneys
    DIURETICS Diuretics are drugs that promote the output of urine excreted by the Kidneys. The primary action of most diuretics is the direct inhibition of Na+ transport at one or more of the four major anatomical sites along the nephron, where Na+ reabsorption takes place. The increased excretion of water and electrolytes by the kidneys is dependent on three different processes viz., glomerular filtration, tubular reabsorption (active and passive) and tubular secretion. Diuretics are very effective in the treatment of Cardiac oedema, specifically the one related with congestive heart failure. They are employed extensively in various types of disorders, for example, nephritic syndrome, diabetes insipidus, nutritional oedema, cirrhosis of the liver, hypertension, oedema of pregnancy and also to lower intraocular and cerebrospinal fluid pressure. Therapeutic Uses of Diuretics i) Congestive Heart Failure: The choice of the diuretic would depend on the severity of the disorder. In an emergency like acute pulmonary oedema, intravenous Furosemide or Sodium ethacrynate may be given. In less severe cases. Hydrochlorothiazide or Chlorthalidone may be used. Potassium-sparing diuretics like Spironolactone or Triamterene may be added to thiazide therapy. ii) Essential hypertension: The thiazides usually sever as primary antihypertensive agents. They may be used as sole agents in patients with mild hypertension or combined with other antihypertensives in more severe cases. iii) Hepatic cirrhosis: Potassium-sparing diuretics like Spironolactone may be employed. If Spironolactone alone fails, then a thiazide diuretic can be added cautiously. Furosemide or Ethacrymnic acid may have to be used if the oedema is regractory, together with spironolactone to lessen potassium loss. Serum potassium levels should be monitored periodically.
    [Show full text]
  • Extracts from PRAC Recommendations on Signals Adopted at the 9-12 March 2020 PRAC
    6 April 20201 EMA/PRAC/111218/2020 Corr2,3 Pharmacovigilance Risk Assessment Committee (PRAC) New product information wording – Extracts from PRAC recommendations on signals Adopted at the 9-12 March 2020 PRAC The product information wording in this document is extracted from the document entitled ‘PRAC recommendations on signals’ which contains the whole text of the PRAC recommendations for product information update, as well as some general guidance on the handling of signals. It can be found here (in English only). New text to be added to the product information is underlined. Current text to be deleted is struck through. 1. Immune check point inhibitors: atezolizumab; cemiplimab; durvalumab – Tuberculosis (EPITT no 19464) IMFINZI (durvalumab) Summary of product characteristics 4.4. Special warnings and precautions for use Immune-mediated pneumonitis [..] Patients with sSuspected pneumonitis should be evaluated confirmed with radiographic imaging and other infectious and disease-related aetiologies excluded, and managed as recommended in section 4.2. LIBTAYO (cemiplimab) Summary of product characteristics 1 Expected publication date. The actual publication date can be checked on the webpage dedicated to PRAC recommendations on safety signals. 2 A footnote was deleted on 8 April 2020 for the signal on thiazide and thiazide-like diuretics (see page 3). 3 A minor edit was implemented in the product information of the signal on thiazide and thiazide-like diuretics on 5 June 2020 (see page 4). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • US20050113367A1.Pdf
    US 20050113367A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0113367 A1 Sada et al. (43) Pub. Date: May 26, 2005 (54) PHARMACEUTICAL COMPOSITION (52) U.S. Cl. ......................................... 514/223.5; 514/381 (75) Inventors: Toshio Sada, Tokyo (JP); Makoto (57) ABSTRACT Mizuno, Funabashi-shi (JP) A pharmaceutical composition which comprises (i) an Correspondence Address: angiotensin II receptor antagonist having the following FRISHAUF, HOLTZ, GOODMAN & CHICK, formula (I), a pharmacologically acceptable Salt thereof, a PC pharmacologically acceptable ester thereof or a pharmaco 767 THIRDAVENUE logically acceptable Salt of Such ester, and (ii) a diuretic 25TH FLOOR which is at least one thiazide compound: NEW YORK, NY 10017-2023 (US) (73) Assignee: SANKYO COMPANY, LIMITED, (I) Tokyo (JP) HC (21) Appl. No.: 11/020,624 CH N OH (22) Filed: Dec. 23, 2004 Related U.S. Application Data --> (63) Continuation of application No. 10/442,874, filed on May 20, 2003, now Pat. No. 6,878,703, which is a continuation of application No. PCT/JP01/10095, filed on Nov. 19, 2001. (30) Foreign Application Priority Data Nov. 21, 2000 (JP). 2000-354327 May 31, 2001 (JP)...................................... 2001-164009 Publication Classification The pharmaceutical composition has an excellent hypoten Sive effect and low toxicity, and therefore is useful as a (51) Int. Cl." .................... A61K 3.1/549; A61K 31/4178 medicament for treating hypertension or heart disease. US 2005/0113367 A1 May 26, 2005 PHARMACEUTICAL COMPOSITION nist and one or more diuretics to warm-blooded animals (particularly humans) at effective doses, and a pharmaceu CROSS-REFERENCE TO RELATED tical composition for administering Simultaneously or APPLICATIONS Sequentially a specific angiotensin II receptor antagonist and one or more diuretics for preventing or treating hyperten 0001.
    [Show full text]
  • Using Medications, Cosmetics, Or Eating Certain Foods Can Increase Sensitivity to Ultraviolet Radiation
    USING MEDICATIONS, COSMETICS, OR EATING CERTAIN FOODS CAN INCREASE SENSITIVITY TO ULTRAVIOLET RADIATION. INDIVIDUALS SHOULD CONSULT A PHYSICIAN BEFORE USING A SUNLAMP, IF THEY ARE TAKING MEDICATIONS. THE ITEMS LISTED ARE POTENTIAL PHOTOSENSITIZING AGENTS THAT MAY INCREASE SENSITIVITY TO ULTRAVIOLET LIGHT THAT MAY RESULT IN A PHOTOTOXIC OR PHOTOALLERGIC RESPONSES. PHOTOSENSITIZING MEDICATIONS Acetazolamide Amiloride+Hydrochlorothizide Amiodarone Amitriptyline Amoxapine Astemizole Atenolol+Chlorthalidone Auranofin Azatadine (Optimine) Azatidine+Pseudoephedrine Bendroflumethiazide Benzthiazide Bromodiphenhydramine Bromopheniramine Captopril Captopril+Hydrochlorothiazide Carbaamazepine Chlordiazepoxide+Amitriptyline Chlorothiazide Chlorpheniramine Chlorpheniramin+DPseudoephedrine Chlorpromazine Chlorpheniramine+Phenylopropanolamine Chlorpropamide Chlorprothixene Chlorthalidone Chlorthalidone+Reserpine Ciprofloxacin Clemastine Clofazime ClonidineChlorthalisone+Coal Tar Coal Tar Contraceptive (oral) Cyclobenzaprine Cyproheptadine Dacarcazine Danazol Demeclocycline Desipramine Dexchlorpheniramine Diclofenac Diflunisal Ditiazem Diphenhydramine Diphenylpyraline Doxepin Doxycycline Doxycycline Hyclate Enalapril Enalapril+Hydrochlorothiazide Erythromycin Ethylsuccinate+Sulfisoxazole Estrogens Estrogens Ethionamide Etretinate Floxuridine Flucytosine Fluorouracil Fluphenazine Flubiprofen Flutamide Gentamicin Glipizide Glyburide Gold Salts (compounds) Gold Sodium Thiomalate Griseofulvin Griseofulvin Ultramicrosize Griseofulvin+Hydrochlorothiazide Haloperidol
    [Show full text]
  • Diuretics -August 2014
    Indian Health Service National Pharmacy and Therapeutics Committee Formulary Brief: Diuretics -August 2014- Background: The IHS National Pharmacy and Therapeutics Committee (NPTC) reviewed the diuretics class at the August 2014 meeting. The last review of this class occurred two years ago with the addition of chlorthalidone to the National Core Formulary (NCF). However, with the release of JNC 8 it was decided to review the class again to evaluate if any other modifications were necessary. The discussion included clinical, utilization and procurement data for this class of medications. This discussion did not lead to a formulary modification; however it was felt that a formulary brief would be of benefit to IHS providers. Discussion: Historically, diuretics have been the mainstay for the treatment of hypertension and the first line agent. Worldwide hydrochlorothiazide (HCTZ) is the most widely prescribed medication for blood pressure.1 The publishing of JNC 8 reinforced thiazide-type diuretics as being the first line choice for the treatment of hypertension with a review of the most current clinical studies (only RTCs were reviewed by the panel). The following is the recommendation from JNC 8 and is rated a grade B: Recommendation 6: In the general nonblack population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic, calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI), or angiotensin receptor blocker (ARB). (Moderate Recommendation) The main difference between JNC 7 and JNC 8 is although thiazide-type diuretics have been show in studies to have a more potent effect at lowering blood pressure than CCB, ACEI and ARB, these agents can also be used as first line therapy depending on therapeutic necessity.
    [Show full text]
  • Polythiazide in the Treatment of Congestive Heart Failure
    Henry Ford Hospital Medical Journal Volume 10 | Number 4 Article 4 12-1962 Polythiazide In The rT eatment Of Congestive Heart Failure John W. Keyes Gerald M. Breneman Jose R. De Jesus Jr. Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Keyes, John W.; Breneman, Gerald M.; and De Jesus, Jose R. Jr. (1962) "Polythiazide In The rT eatment Of Congestive Heart Failure," Henry Ford Hospital Medical Bulletin : Vol. 10 : No. 4 , 555-561. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol10/iss4/4 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact [email protected]. Henry Ford Hosp. Med. Bull. Vol. 10, December, 1962 POLYTHIAZIDE IN THE TREATMENT OF CONGESTIVE HEART FAILURE JOHN W. KEYES, M.D., GERALD M. BRENEMAN, M.D., JOSE R. DE JESUS, JR., M.D."' THE INTRODUCTION of chlorothiazide and its analogues in the past few years have made available potent oral diuretics which approach the organic mercurial compounds in efficacy. These drugs have shifted the emphasis from parenteral mercury, particularly for the long term management of various derivatives, all appear to be effective and safe diuretics. All of these compounds are active saluretic agents inhibiting tubular reabsorption of sodium, and causing increased excretion of chlorides. Potassium excretion is also significantly increased, but varies somewhat, depending on the particular analogue in use.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • Change Notification No 9
    Northern Ireland BLOOD TRANSFUSION SERVICE Date of publication: 24th April 2006 Implementation: To be determined by each Service Change Notification UK National Blood Services No. 9 - 2006 Appendix 5 – Treatment for High Blood Pressure Applies to Tissue Donor Selection Guidelines – Bone Marrow and PBSC and also appears as Appendix 6 – Treatment for High Blood Pressure Applies to Donor Selection Guidelines - Whole Blood and Components The entry in both the guidelines is the same: Treatment for High Blood Pressure Donors who have been diagnosed with high blood pressure may donate provided that: 1. They have not suffered any adverse effects of raised blood pressure (BP) such as heart disease (angina, heart attack or heart failure), stroke, transient ischaemic attack (TIA or mini-stroke), or peripheral vascular disease (intermittent claudication, gangrene). 2. They are taking only a Beta(ß)-blocker and/or diuretic as their treatment for the raised BP. The list below shows the proper and trade names of allowed drugs. It is important to note that this list is not exclusive and that these drugs may be used to treat other conditions such as heart failure and abnormal heart rhythms (arrhythmia); both of which would mean the donor must not donate. Other medication should be assessed independently. 3. Treatment is stable. This requires: That the donor is well and not having any problems with feeling faint, fainting or giddiness. They have been on the same dose of medication for at least a month. They are not undergoing tests to find out the underlying
    [Show full text]